433 related articles for article (PubMed ID: 18307371)
1. Population pharmacokinetics of meropenem in critically ill patients undergoing continuous renal replacement therapy.
Isla A; Rodríguez-Gascón A; Trocóniz IF; Bueno L; Solinís MA; Maynar J; Sánchez-Izquierdo JA; Pedraz JL
Clin Pharmacokinet; 2008; 47(3):173-80. PubMed ID: 18307371
[TBL] [Abstract][Full Text] [Related]
2. Meropenem population pharmacokinetics in critically ill patients with septic shock and continuous renal replacement therapy: influence of residual diuresis on dose requirements.
Ulldemolins M; Soy D; Llaurado-Serra M; Vaquer S; Castro P; Rodríguez AH; Pontes C; Calvo G; Torres A; Martín-Loeches I
Antimicrob Agents Chemother; 2015 Sep; 59(9):5520-8. PubMed ID: 26124172
[TBL] [Abstract][Full Text] [Related]
3. Effect of renal clearance and continuous renal replacement therapy on appropriateness of recommended meropenem dosing regimens in critically ill patients with susceptible life-threatening infections.
Burger R; Guidi M; Calpini V; Lamoth F; Decosterd L; Robatel C; Buclin T; Csajka C; Marchetti O
J Antimicrob Chemother; 2018 Dec; 73(12):3413-3422. PubMed ID: 30304491
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetics of standard-dose meropenem in critically ill patients on continuous renal replacement therapy: a prospective observational trial.
Onichimowski D; Będźkowska A; Ziółkowski H; Jaroszewski J; Borys M; Czuczwar M; Wiczling P
Pharmacol Rep; 2020 Jun; 72(3):719-729. PubMed ID: 32301057
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetics of meropenem in critically ill children with different renal functions.
Rapp M; Urien S; Foissac F; Béranger A; Bouazza N; Benaboud S; Bille E; Zheng Y; Gana I; Moulin F; Lesage F; Renolleau S; Tréluyer JM; Hirt D; Oualha M
Eur J Clin Pharmacol; 2020 Jan; 76(1):61-71. PubMed ID: 31654149
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of meropenem in children receiving continuous renal replacement therapy: Validation of clinical trial simulations.
Nehus EJ; Mizuno T; Cox S; Goldstein SL; Vinks AA
J Clin Pharmacol; 2016 Mar; 56(3):291-7. PubMed ID: 26222329
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and pharmacodynamics of continuous infusion meropenem in overweight, obese, and morbidly obese patients with stable and unstable kidney function: a step toward dose optimization for the treatment of severe gram-negative bacterial infections.
Pai MP; Cojutti P; Pea F
Clin Pharmacokinet; 2015 Sep; 54(9):933-41. PubMed ID: 25850987
[TBL] [Abstract][Full Text] [Related]
8. Population Pharmacokinetic Meta-Analysis and Dosing Recommendation for Meropenem in Critically Ill Patients Receiving Continuous Renal Replacement Therapy.
Peng Y; Cheng Z; Xie F
Antimicrob Agents Chemother; 2022 Sep; 66(9):e0082222. PubMed ID: 36005753
[TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetics of meropenem during continuous infusion in surgical ICU patients.
Kees MG; Minichmayr IK; Moritz S; Beck S; Wicha SG; Kees F; Kloft C; Steinke T
J Clin Pharmacol; 2016 Mar; 56(3):307-15. PubMed ID: 26222202
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and the most suitable regimen of panipenem/beta mipron in critically ill patients receiving continuous renal replacement therapy: a pilot study.
Hayakawa M; Ito Y; Fujita I; Iseki K; Gando S
ASAIO J; 2006; 52(4):398-403. PubMed ID: 16883119
[TBL] [Abstract][Full Text] [Related]
11. A Nonparametric Pharmacokinetic Approach to Determine the Optimal Dosing Regimen for 30-Minute and 3-Hour Meropenem Infusions in Critically Ill Patients.
Mathew SK; Mathew BS; Neely MN; Naik GS; Prabha R; Jacob GG; K S; Fleming DH
Ther Drug Monit; 2016 Oct; 38(5):593-9. PubMed ID: 27454665
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetics and probability of target attainment of meropenem in critically ill patients.
Mattioli F; Fucile C; Del Bono V; Marini V; Parisini A; Molin A; Zuccoli ML; Milano G; Danesi R; Marchese A; Polillo M; Viscoli C; Pelosi P; Martelli A; Di Paolo A
Eur J Clin Pharmacol; 2016 Jul; 72(7):839-48. PubMed ID: 27048201
[TBL] [Abstract][Full Text] [Related]
13. The combined effects of extracorporeal membrane oxygenation and renal replacement therapy on meropenem pharmacokinetics: a matched cohort study.
Shekar K; Fraser JF; Taccone FS; Welch S; Wallis SC; Mullany DV; Lipman J; Roberts JA;
Crit Care; 2014 Dec; 18(6):565. PubMed ID: 25636084
[TBL] [Abstract][Full Text] [Related]
14. Dosing nomograms for attaining optimum concentrations of meropenem by continuous infusion in critically ill patients with severe gram-negative infections: a pharmacokinetics/pharmacodynamics-based approach.
Pea F; Viale P; Cojutti P; Furlanut M
Antimicrob Agents Chemother; 2012 Dec; 56(12):6343-8. PubMed ID: 23045356
[TBL] [Abstract][Full Text] [Related]
15. Assessment of pharmacokinetic changes of meropenem during therapy in septic critically ill patients.
Goncalves-Pereira J; Silva NE; Mateus A; Pinho C; Povoa P
BMC Pharmacol Toxicol; 2014 Apr; 15():21. PubMed ID: 24731745
[TBL] [Abstract][Full Text] [Related]
16. Population Pharmacokinetics and Dosing Optimization of Piperacillin-Tazobactam in Critically Ill Patients on Extracorporeal Membrane Oxygenation and the Influence of Concomitant Renal Replacement Therapy.
Hahn J; Min KL; Kang S; Yang S; Park MS; Wi J; Chang MJ
Microbiol Spectr; 2021 Dec; 9(3):e0063321. PubMed ID: 34937189
[TBL] [Abstract][Full Text] [Related]
17. Beta-lactam dosing in critically ill patients with septic shock and continuous renal replacement therapy.
Ulldemolins M; Vaquer S; Llauradó-Serra M; Pontes C; Calvo G; Soy D; Martín-Loeches I
Crit Care; 2014 Jun; 18(3):227. PubMed ID: 25042938
[TBL] [Abstract][Full Text] [Related]
18. Population Pharmacokinetics and Pharmacodynamics of Meropenem in Critically Ill Patients: How to Achieve Best Dosage Regimen According to the Clinical Situation.
O'Jeanson A; Larcher R; Le Souder C; Djebli N; Khier S
Eur J Drug Metab Pharmacokinet; 2021 Sep; 46(5):695-705. PubMed ID: 34403127
[TBL] [Abstract][Full Text] [Related]
19. Optimising meropenem dosing in critically ill Australian Indigenous patients with severe sepsis.
Tsai D; Stewart P; Goud R; Gourley S; Hewagama S; Krishnaswamy S; Wallis SC; Lipman J; Roberts JA
Int J Antimicrob Agents; 2016 Nov; 48(5):542-546. PubMed ID: 27771187
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of meropenem in critically ill patients receiving continuous venovenous haemofiltration: a randomised controlled trial of continuous infusion versus intermittent bolus administration.
Jamal JA; Mat-Nor MB; Mohamad-Nor FS; Udy AA; Wallis SC; Lipman J; Roberts JA
Int J Antimicrob Agents; 2015 Jan; 45(1):41-5. PubMed ID: 25455853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
